N'-[7-(4-propylphenyl)-1,6-naphthyridin-5-yl]propane-1,3-diamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N'-[7-(4-propylphenyl)-1,6-naphthyridin-5-yl]propane-1,3-diamine
• 化学式: C₂₀H₂₄N₄
• 分子量: 320.4
• InChiKey: XBKMODQTKKTESZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  63.8
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：EP3131582A1

  公开（公告）日：2017-02-22
• [EN] PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES<br/>[FR] COMPOSITIONS PHARMACEUTIQUES DESTINÉES AU TRAITEMENT DES MALADIES LIÉES AU RÉGULATEUR DE LA CONDUCTANCE TRANSMEMBRANAIRE DE LA MUCOVISCIDOSE
  申请人：VERTEX PHARMA

  公开号：WO2015160787A1

  公开（公告）日：2015-10-22

  The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed.